HK2 and systemic lupus erythematosus: In addition, we summarized some drugs that target metabolic pathways; for example, 2-deoxy-d-glucose (2-DG), a drug that can compete with glucose in binding to hexokinase II (HKII) to inhibit cellular glycolysis activity and regulate the glycolytic pathway, induces Treg cell differentiation and suppression and alleviates the progression of systemic lupus erythematosus (SLE) in TC mice (209).